Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2019 10:19 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Presentation of Initial Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Refractory Advanced Melanoma at SMR 2019 Congress

First 10 checkpoint-refractory melanoma patients treatedEstablished safety profiles of PV-10 and KEYTRUDA were maintained20% ORR and 40% DCR (RECIST 1.1)Changes in immune system activation biomarkers...